Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation

Choon Hyuck David Kwon, Kyung Suk Suh, Nam Joon Yi, Seong Hwan Chang, Yong Beom Cho, Jai Young Cho, Hoan Jong Lee, Jeong Kee Seo, Kuhn Uk Lee

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Liver recipients who have antibodies to hepatitis B core antigen (anti-HBc) or received an anti-HBc positive liver graft are at risk of acquiring de novo hepatitis B infection so a life long prophylaxis is required. A post-transplant vaccination against hepatitis B virus (HBV) can offer a better alternative than either hepatitis B hyperimmune globulin (HBIG) or lamivudine. This study investigated the course of anti-HBs titer after vaccination and analyzed the factors that influence the response. Between October 1999 and February 2003, 37 pediatric patients were given a post-transplant vaccination when an anti-HBc positive graft was used, the recipient was anti-HBc positive, or when anti-HBs titer was below 20 IU/L irrespective of the serological status. Thirty-three patients responded to the vaccine and did not require further HBIG injections at a mean follow up of 33.6 months. Fifteen patients were good responder and only needed a single set of vaccines, and 18 were poor responder needing additional boosters. Two patients developed de novo hepatitis B infection and two required additional HBIG injections. Preoperative severity of liver disease, serological status of HBV of recipient or donor, use of HBIG or pulse steroid therapy, type of vaccines, and dose or time interval between doses had no influence on response rate. Recipients with a high preoperative anti-HB titer, small graft-recipient weight ratio (GRWR), greater catch up growth, heavier body weight, lower tacrolimus level at the time of vaccination, and longer time interval between transplant or steroid medication and vaccination yielded good response. If well tailored, post-transplant vaccination can be effective and offer patients prophylaxis against de novo hepatitis B infection for a prolonged period of time.

Original languageEnglish
Pages (from-to)479-486
Number of pages8
JournalPediatric Transplantation
Volume10
Issue number4
DOIs
StatePublished - 1 Jun 2006

Fingerprint

Hepatitis B
Vaccination
Transplantation
Hepatitis B Core Antigens
Pediatrics
Transplants
Liver
Antibodies
Hepatitis B virus
Vaccines
Infection
Steroids
Active Immunotherapy
Injections
Lamivudine
Tacrolimus
Liver Diseases
Body Weight
Tissue Donors
Weights and Measures

Keywords

  • De novo hepatitis B
  • Hepatitis B core antibody
  • Hepatitis B surface antibody
  • Occult hepatitis
  • Prophylaxis

Cite this

Kwon, Choon Hyuck David ; Suh, Kyung Suk ; Yi, Nam Joon ; Chang, Seong Hwan ; Cho, Yong Beom ; Cho, Jai Young ; Lee, Hoan Jong ; Seo, Jeong Kee ; Lee, Kuhn Uk. / Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. In: Pediatric Transplantation. 2006 ; Vol. 10, No. 4. pp. 479-486.
@article{5f308ac1c11a40c1aec220808300057a,
title = "Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation",
abstract = "Liver recipients who have antibodies to hepatitis B core antigen (anti-HBc) or received an anti-HBc positive liver graft are at risk of acquiring de novo hepatitis B infection so a life long prophylaxis is required. A post-transplant vaccination against hepatitis B virus (HBV) can offer a better alternative than either hepatitis B hyperimmune globulin (HBIG) or lamivudine. This study investigated the course of anti-HBs titer after vaccination and analyzed the factors that influence the response. Between October 1999 and February 2003, 37 pediatric patients were given a post-transplant vaccination when an anti-HBc positive graft was used, the recipient was anti-HBc positive, or when anti-HBs titer was below 20 IU/L irrespective of the serological status. Thirty-three patients responded to the vaccine and did not require further HBIG injections at a mean follow up of 33.6 months. Fifteen patients were good responder and only needed a single set of vaccines, and 18 were poor responder needing additional boosters. Two patients developed de novo hepatitis B infection and two required additional HBIG injections. Preoperative severity of liver disease, serological status of HBV of recipient or donor, use of HBIG or pulse steroid therapy, type of vaccines, and dose or time interval between doses had no influence on response rate. Recipients with a high preoperative anti-HB titer, small graft-recipient weight ratio (GRWR), greater catch up growth, heavier body weight, lower tacrolimus level at the time of vaccination, and longer time interval between transplant or steroid medication and vaccination yielded good response. If well tailored, post-transplant vaccination can be effective and offer patients prophylaxis against de novo hepatitis B infection for a prolonged period of time.",
keywords = "De novo hepatitis B, Hepatitis B core antibody, Hepatitis B surface antibody, Occult hepatitis, Prophylaxis",
author = "Kwon, {Choon Hyuck David} and Suh, {Kyung Suk} and Yi, {Nam Joon} and Chang, {Seong Hwan} and Cho, {Yong Beom} and Cho, {Jai Young} and Lee, {Hoan Jong} and Seo, {Jeong Kee} and Lee, {Kuhn Uk}",
year = "2006",
month = "6",
day = "1",
doi = "10.1111/j.1399-3046.2006.00540.x",
language = "English",
volume = "10",
pages = "479--486",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. / Kwon, Choon Hyuck David; Suh, Kyung Suk; Yi, Nam Joon; Chang, Seong Hwan; Cho, Yong Beom; Cho, Jai Young; Lee, Hoan Jong; Seo, Jeong Kee; Lee, Kuhn Uk.

In: Pediatric Transplantation, Vol. 10, No. 4, 01.06.2006, p. 479-486.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation

AU - Kwon, Choon Hyuck David

AU - Suh, Kyung Suk

AU - Yi, Nam Joon

AU - Chang, Seong Hwan

AU - Cho, Yong Beom

AU - Cho, Jai Young

AU - Lee, Hoan Jong

AU - Seo, Jeong Kee

AU - Lee, Kuhn Uk

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Liver recipients who have antibodies to hepatitis B core antigen (anti-HBc) or received an anti-HBc positive liver graft are at risk of acquiring de novo hepatitis B infection so a life long prophylaxis is required. A post-transplant vaccination against hepatitis B virus (HBV) can offer a better alternative than either hepatitis B hyperimmune globulin (HBIG) or lamivudine. This study investigated the course of anti-HBs titer after vaccination and analyzed the factors that influence the response. Between October 1999 and February 2003, 37 pediatric patients were given a post-transplant vaccination when an anti-HBc positive graft was used, the recipient was anti-HBc positive, or when anti-HBs titer was below 20 IU/L irrespective of the serological status. Thirty-three patients responded to the vaccine and did not require further HBIG injections at a mean follow up of 33.6 months. Fifteen patients were good responder and only needed a single set of vaccines, and 18 were poor responder needing additional boosters. Two patients developed de novo hepatitis B infection and two required additional HBIG injections. Preoperative severity of liver disease, serological status of HBV of recipient or donor, use of HBIG or pulse steroid therapy, type of vaccines, and dose or time interval between doses had no influence on response rate. Recipients with a high preoperative anti-HB titer, small graft-recipient weight ratio (GRWR), greater catch up growth, heavier body weight, lower tacrolimus level at the time of vaccination, and longer time interval between transplant or steroid medication and vaccination yielded good response. If well tailored, post-transplant vaccination can be effective and offer patients prophylaxis against de novo hepatitis B infection for a prolonged period of time.

AB - Liver recipients who have antibodies to hepatitis B core antigen (anti-HBc) or received an anti-HBc positive liver graft are at risk of acquiring de novo hepatitis B infection so a life long prophylaxis is required. A post-transplant vaccination against hepatitis B virus (HBV) can offer a better alternative than either hepatitis B hyperimmune globulin (HBIG) or lamivudine. This study investigated the course of anti-HBs titer after vaccination and analyzed the factors that influence the response. Between October 1999 and February 2003, 37 pediatric patients were given a post-transplant vaccination when an anti-HBc positive graft was used, the recipient was anti-HBc positive, or when anti-HBs titer was below 20 IU/L irrespective of the serological status. Thirty-three patients responded to the vaccine and did not require further HBIG injections at a mean follow up of 33.6 months. Fifteen patients were good responder and only needed a single set of vaccines, and 18 were poor responder needing additional boosters. Two patients developed de novo hepatitis B infection and two required additional HBIG injections. Preoperative severity of liver disease, serological status of HBV of recipient or donor, use of HBIG or pulse steroid therapy, type of vaccines, and dose or time interval between doses had no influence on response rate. Recipients with a high preoperative anti-HB titer, small graft-recipient weight ratio (GRWR), greater catch up growth, heavier body weight, lower tacrolimus level at the time of vaccination, and longer time interval between transplant or steroid medication and vaccination yielded good response. If well tailored, post-transplant vaccination can be effective and offer patients prophylaxis against de novo hepatitis B infection for a prolonged period of time.

KW - De novo hepatitis B

KW - Hepatitis B core antibody

KW - Hepatitis B surface antibody

KW - Occult hepatitis

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=33646869649&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2006.00540.x

DO - 10.1111/j.1399-3046.2006.00540.x

M3 - Article

C2 - 16712607

AN - SCOPUS:33646869649

VL - 10

SP - 479

EP - 486

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 4

ER -